Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Inovio Pharmaceuticals, Inc is a biotechnology business based in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Inovio Pharmaceuticals employs 190 staff and has a trailing 12-month revenue of around USD$2.7 million.
Since the stock market crash in March caused by coronavirus, Inovio Pharmaceuticals's share price has had significant positive movement.
Its last market close was USD$17, which is 77.97% up on its pre-crash value of USD$3.745 and 441.40% up on the lowest point reached during the March crash when the shares fell as low as USD$3.14.
If you had bought USD$1,000 worth of Inovio Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$1,693.07 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$4,347.75.
|Latest market close||USD$17|
|52-week range||USD$1.96 - USD$33.79|
|50-day moving average||USD$14.2144|
|200-day moving average||USD$14.3568|
|Wall St. target price||USD$19|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.215|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-14)||50.18%|
|1 month (2020-08-21)||20.57%|
|3 months (2020-06-19)||19.13%|
|6 months (2020-03-20)||135.46%|
|1 year (2019-09-20)||585.48%|
|2 years (2018-09-21)||259.41%|
|3 years (2017-09-21)||170.27%|
|5 years (2015-09-21)||133.20%|
|Revenue TTM||USD$2.7 million|
|Gross profit TTM||USD$-82,005,389|
|Return on assets TTM||-22.79%|
|Return on equity TTM||-184.48%|
|Market capitalisation||USD$2.8 billion|
TTM: trailing 12 months
There are currently 30.9 million Inovio Pharmaceuticals shares held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 20% up from 25.8 million last month.
There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals shares can be evaluated.
Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals shares currently shorted divided by the average quantity of Inovio Pharmaceuticals shares traded daily (recently around 9.4 million). Inovio Pharmaceuticals's SIR currently stands at 3.3. In other words for every 100,000 Inovio Pharmaceuticals shares traded daily on the market, roughly 3300 shares are currently held short.
However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals shares, or, against the total number of tradable Inovio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.31% of the outstanding shares (for every 100,000 Inovio Pharmaceuticals shares in existence, roughly 310 shares are currently held short) or 0.3158% of the tradable shares (for every 100,000 tradable Inovio Pharmaceuticals shares, roughly 316 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inovio Pharmaceuticals.
Find out more about how you can short Inovio Pharmaceuticals stock.
We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.
Inovio Pharmaceuticals's shares were split on a 1:4 basis on 6 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.
Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as $1.96 up to $33.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 1.0903. This would suggest that Inovio Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.